|Articles|April 15, 2002
Excludes most of Asia: Tacrolimus licensing deal links Sucampo, Fujisawa
Bethesda, MD-Sucampo Pharmaceuticals Inc. has won the exclusive right to license Fujisawa's tacrolimus for ophthalmic use in the United States, Europe, and much of the world.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
SubscribeAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FDA grants RMAT designation to Emmecell's EO2002 for corneal endothelial disease
2
Opus Genetics reaches FDA alignment on phase 3 registrational design for OPGx-LCA5 gene therapy
3
NeuroOp Guru: What a big data study reveals about NAION and stroke risk
4
Port Delivery System Therapies in Retinal Vascular Diseases
5


















